



# An Open Label Extension Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) $\beta$ -Thalassemia Subjects

04/12/2024 10:36:32

## Main Information

**Primary registry identifying number**

LBCTR2019070220

**Protocol number**

PTG300-03

**MOH registration number**

**Study registered at the country of origin**

Yes

**Study registered at the country of origin: Specify**

**Type of registration**

Prospective

**Type of registration: Justify**

N/A

**Date of registration in national regulatory agency**

19/06/2019

**Primary sponsor**

Protagonist Therapeutics Inc

**Primary sponsor: Country of origin**

USA

**Date of registration in primary registry**

23/05/2022

**Date of registration in national regulatory agency**

19/06/2019

**Public title**

An Open Label Extension Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD)  $\beta$ -Thalassemia Subjects

**Acronym**

**Scientific title**

An Open Label Extension Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD)  $\beta$ -Thalassemia Subjects

**Acronym**

**Brief summary of the study: English**

This is an open-label, long term extension study for subjects completing study PTG-300-02. After completing the previous study, eligible subjects who choose to continue treatment may enroll in the PTG-300-03 study. The safety evaluation done at the end of study PTG-300-02 will be used to confirm subject eligibility for this study (see Screening in Study Procedure section). No interruption of PTG-300 treatment is expected with the transition between studies.

**Brief summary of the study: Arabic**

PTG-300-03. بعد الانتهاء من الدراسة السابقة، قد يتم تسجيل الأشخاص المؤهلين الذين يختارون مواصلة العلاج في دراسة PTG-300-03. دراسة تمديدية مفتوحة التسمية للأشخاص الذين اكملوا دراسة PTG-300-02 لتأكيد أهلية الموضوع لهذه الدراسة. لا يتوقع أي انقطاع للعلاج مع الانتقال بين الدراسات. سيتم استخدام تقييم السلامة الذي تم في نهاية الدراسة PTG-300-02 لتأكيد أهلية الموضوع لهذه الدراسة. لا يتوقع أي انقطاع للعلاج مع الانتقال بين الدراسات.

**Health conditions/problem studied: Specify**

Chronic anemia due to ineffective erythropoiesis (IE) in subjects with  $\beta$  thalassemia

**Interventions: Specify**





Subjects rolling over from the PTG-300-02 study, who meet the response criteria defined for this study at the last dose received in study PTG-300-02, will continue to receive the same dose in PTG-300-03.

Subjects who did not meet response criteria defined for this study at the last dose received in study PTG-300-02, will start PTG-300-03 at the next higher dose level.

**Key inclusion and exclusion criteria: Inclusion criteria**

1. NTD and TD  $\beta$ -thalassemia subjects who completed Week 12 and Week 16 respectively in Study PTG-300-02.
2. Women of childbearing potential (WOCBP) and men agree to use a highly effective contraceptive measure (base on the Clinical Trial Facilitation Group [CTFG]) during the duration of the study and for 4 weeks after the last dose of study drug in the case of women and 90 days after the last dose of study drug in the case of men.
3. For WOCBP, a negative urine pregnancy test within 24 hours prior to the first dose of study medication in this study.
4. Subjects or legal guardians (in the case of minors) understand the study procedures and agree to participate in the study by giving written informed consent.
5. Subjects, or legal representative (in the case of minors) are willing and able to adhere to the study visit schedule and other protocol requirements.
6. Subjects between 12-<18 years of age understand and provide the assent to participate in the study, according to local guidelines.

**Key inclusion and exclusion criteria: Gender**

Both

**Key inclusion and exclusion criteria: Specify gender**

**Key inclusion and exclusion criteria: Age minimum**

12

**Key inclusion and exclusion criteria: Age maximum**

65

**Key inclusion and exclusion criteria: Exclusion criteria**

1. Subjects who discontinued prematurely from study 300-02 (before Week 12 in NTD and Week 16 in TD)
2. Clinically meaningful laboratory abnormalities at Screening.
3. Pregnant or lactating females.
4. Current history of alcohol dependence or illicit drug use.
5. Subject has a concurrent clinically significant, unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic or other medical disorder that, in the opinion of the Investigator, might confound the results of the study or pose additional risk to the subject by their participation in the study.
6. Subject is mentally or legally incapacitated at the time of Screening visit or has a history of clinically significant psychiatric disorders that would impact the subject's ability to participate in the trial according to the Investigator.
7. Concurrent participation in any other interventional study.

**Type of study**

Interventional

**Type of intervention**

Pharmaceutical

**Type of intervention: Specify type**

N/A

**Trial scope**

Therapy

**Trial scope: Specify scope**

N/A

**Study design: Allocation**

N/A: Single arm study

**Study design: Masking**

Open (masking not used)

**Study design: Control**

N/A

**Study phase**

2

**Study design: Purpose**

Treatment

**Study design: Specify purpose**

N/A

**Study design: Assignment**

Single

**Study design: Specify assignment**

N/A

**IMP has market authorization**

No

**IMP has market authorization: Specify**

**Name of IMP**

**Year of authorization**

**Month of authorization**



PTG-300

**Type of IMP**

Cell therapy

**Pharmaceutical class**

PTG-300 is a peptidic agent structurally related to natural hepcidin that mimics its inhibitory activity on ferroportin.

**Therapeutic indication**

$\beta$  thalassemia

**Therapeutic benefit**

Administration of PTG-300 may result in iron redistribution in  $\beta$ -thalassemia subjects with potentially beneficial effects on erythropoiesis and consequently improvements in chronic anemia. This improvement in ineffective erythropoiesis may result in a clinical benefit both in NTD and in TD  $\beta$ -thalassemia subjects, by improving the symptomatology of the chronic anemia and the complications of the extramedullary hematopoiesis in the first group and by decreasing the need for transfusions in the latter.

**Study model**

N/A

**Study model: Explain model**

N/A

**Study model: Specify model**

N/A

**Time perspective**

N/A

**Time perspective: Explain time perspective**

N/A

**Time perspective: Specify perspective**

N/A

**Target follow-up duration**

**Target follow-up duration: Unit**

**Number of groups/cohorts**

**Biospecimen retention**

Samples without DNA

**Biospecimen description**

Blood samples taken throughout the study will be shipped to ICON lab in Ireland for analysis. These samples will be then stored at ICON Lab by Protagonist Therapeutics for up to 10 years.

**Target sample size**

84

**Actual enrollment target size**

**Date of first enrollment: Type**

Actual

**Date of first enrollment: Date**

07/08/2019

**Date of study closure: Type**

Actual

**Date of study closure: Date**

06/07/2020



<b>Recruitment status</b> Complete	<b>Recruitment status: Specify</b>
<b>Date of completion</b> 22/02/2020	
<b>IPD sharing statement plan</b> No	<b>IPD sharing statement description</b> Not applicable
<b>Additional data URL</b> none	
<b>Admin comments</b>	
<b>Trial status</b> Approved	

## Secondary Identifying Numbers

Full name of issuing authority	Secondary identifying number
Food and Drug Administration	IND

## Sources of Monetary or Material Support

Name
Protagonist Therapeutics.inc

## Secondary Sponsors

Name
Not Applicable

## Contact for Public/Scientific Queries

Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Aziz Zoghbi	MCT-CRO, Berytech Technology and Health, 5th Floor Damascus Road, Beirut, Lebanon	Lebanon	009611612500	zog_az@mct-cro.com	Regional Manager
Scientific	Ali Taher	Chronic Care Center, Hazmieh, Lebanon	Lebanon	009613755669	ataher@aub.edu.lb	PI



## Centers/Hospitals Involved in the Study

Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval
Chronic Care Center	Dr. Ali Taher	Hematology/Oncology	Approved

## Ethics Review

Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
Chronic Care Center	01/06/2019	Michele Abi Saad	cccmass@chroniccare.org.lb	05-455101

## Countries of Recruitment

Name
Lebanon
Thailand
United Kingdom
United States of America
Turkey
Tunisia
Malaysia
Greece
Italy

## Health Conditions or Problems Studied

Condition	Code	Keyword
Thalassemia	Thalassaemia (D56)	Thalassemia



## Interventions

Intervention	Description	Keyword
PTG-300	3mg/week	NA
PTG-300	10mg/week	NA
PTG-300	20mg/week	NA
PTG-300	40mg/week	NA
PTG-300	40 mg every 2 weeks	NA
PTG-300	80 mg/week	NA
PTG-300	80 mg every 2 weeks	NA

## Primary Outcomes

Name	Time Points	Measure
NTD Subjects who achieve an increase in Hgb $\geq 1.0$ g/dL	from pre-treatment baseline without transfusion	Hemoglobin Test
NTD patients: Hgb change	from pre-treatment baseline	Hemoglobin Test
TD Subjects who achieve a $\geq 20\%$ reduction in the red blood cell (RBC) units transfused over 8-week period compared to pre-treatment baseline	over an 8-week period	RBC units transfused
TD patients: Change in the number of units of RBC required	from pre-treatment baseline	RBC units transfused



## Key Secondary Outcomes

Name	Time Points	Measure
NTD patients: Proportion of subjects who achieve an increase in Hgb $\geq 1.5$ g/dL	from pre-treatment baseline without transfusion	Hgb test
Proportion of subjects who achieve a maintenance dose	from pre-treatment baseline	Dose
Hgb level	from pre-treatment baseline	Hgb test
NTD Patients: Duration of Hgb change of $\geq 1.0$ g/dL	from pre-treatment baseline without transfusion	Hgb test
NTD Patients: Duration of Hgb change of $\geq 1.5$ g/dL from	from pre-treatment baseline without transfusion	Hgb test
Change in the following PD parameters	from pre-treatment baseline	serum iron, ferritin, transferrin saturation (TSAT)
TD Patients: Proportion of subjects who achieve $\geq 33\%$ reduction in the RBC units required over an 8-week period	over an 8-week period	RBC units transfused
TD Patients: Duration of response defined as $\geq 20\%$ reduction in the RBC units	over an 8-week period	RBC units transfused
TD Patients: Number of RBC units required	from pre-treatment baseline	RBC units transfused
TD Patients: Percent change in the RBC units required	from pre-treatment baseline	RBC units transfused
TD: Hgb change	from pre-treatment baseline	Hgb test



## Trial Results

**Summary results**

**Study results globally**

**Date of posting of results summaries**

**Date of first journal publication of results**

**Results URL link**

**Baseline characteristics**

**Participant flow**

**Adverse events**

**Outcome measures**

**URL to protocol files**